DE602004016503D1 - Verfahren zum testen der lkb1-phosphorylierungsaktivität - Google Patents

Verfahren zum testen der lkb1-phosphorylierungsaktivität

Info

Publication number
DE602004016503D1
DE602004016503D1 DE602004016503T DE602004016503T DE602004016503D1 DE 602004016503 D1 DE602004016503 D1 DE 602004016503D1 DE 602004016503 T DE602004016503 T DE 602004016503T DE 602004016503 T DE602004016503 T DE 602004016503T DE 602004016503 D1 DE602004016503 D1 DE 602004016503D1
Authority
DE
Germany
Prior art keywords
ampk
lkb1
activity
substrate kinase
phosphoryling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004016503T
Other languages
English (en)
Inventor
David Carling
Angela Woods
Fiona Leiper
Marian Carlson
Seung Pyo Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Columbia University in the City of New York
Original Assignee
Medical Research Council
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329866A external-priority patent/GB2402938B/en
Application filed by Medical Research Council, Columbia University in the City of New York filed Critical Medical Research Council
Publication of DE602004016503D1 publication Critical patent/DE602004016503D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
DE602004016503T 2003-06-17 2004-06-17 Verfahren zum testen der lkb1-phosphorylierungsaktivität Expired - Lifetime DE602004016503D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47910003P 2003-06-17 2003-06-17
GB0329866A GB2402938B (en) 2003-06-17 2003-12-23 Kinase assay
PCT/GB2004/002584 WO2004113562A1 (en) 2003-06-17 2004-06-17 Method for assaying lkb1 phosphorylation activity

Publications (1)

Publication Number Publication Date
DE602004016503D1 true DE602004016503D1 (de) 2008-10-23

Family

ID=33542697

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016503T Expired - Lifetime DE602004016503D1 (de) 2003-06-17 2004-06-17 Verfahren zum testen der lkb1-phosphorylierungsaktivität

Country Status (7)

Country Link
EP (1) EP1633883B1 (de)
JP (1) JP4651617B2 (de)
AT (1) ATE408023T1 (de)
DE (1) DE602004016503D1 (de)
DK (1) DK1633883T3 (de)
ES (1) ES2313029T3 (de)
WO (1) WO2004113562A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE392433T1 (de) * 2003-07-17 2008-05-15 Univ Dundee Verfahren zur anwendung eines an lkb1/strad/mo25- komplexes
US7439341B2 (en) 2003-11-14 2008-10-21 Integrated Dna Technologies, Inc. Fluorescence quenching azo dyes, their methods of preparation and use
AU2006214892B2 (en) * 2005-02-16 2013-06-27 Kt & G Co., Ltd Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US7476735B2 (en) * 2005-05-20 2009-01-13 Integrated Dna Technologies, Inc. Compounds and methods for labeling oligonucleotides
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
US8916345B2 (en) 2010-03-26 2014-12-23 Integrated Dna Technologies, Inc. Methods for enhancing nucleic acid hybridization
EP2614149B1 (de) 2010-09-07 2015-04-08 Integrated Dna Technologies, Inc. Modifizierungen für antisense-verbindungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311414A1 (en) * 1997-11-27 1999-06-10 Chugai Research Institute For Molecular Medicine, Inc. Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in lkb1 gene
AU2001269785A1 (en) * 2000-06-09 2001-12-17 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids

Also Published As

Publication number Publication date
EP1633883A1 (de) 2006-03-15
EP1633883B1 (de) 2008-09-10
DK1633883T3 (da) 2009-01-26
ATE408023T1 (de) 2008-09-15
JP4651617B2 (ja) 2011-03-16
ES2313029T3 (es) 2009-03-01
WO2004113562A1 (en) 2004-12-29
JP2007520199A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
WO2007120480A3 (en) Systems and methods for predicting effectiveness in the treatment of psychiatric disorders, including depression
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
MX2010002005A (es) Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
MX2010002004A (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
WO2005111233A3 (en) Methods and kits to detect hereditary angioedema type iii
WO2004089286A3 (en) Novel compounds and compositions as protein kinase inhibitors
WO2007030693A3 (en) Methods for promoting stem cell proliferation and survival
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
WO2007064882A3 (en) Treatment of conditions involving demyelination
WO2007047754A3 (en) Mtor pathway theranostic
WO2003103697A3 (en) USE OF COMPOUNDS HAVING GIP ACTIVITY IN THE TREATMENT OF DISORDERS ASSOCIATED WITH ABNORMAL CELL LOSS AND / OR IN THE TREATMENT OF OBESITY
DE602004028286D1 (de) Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen
ATE408023T1 (de) Verfahren zum testen der lkb1- phosphorylierungsaktivität
WO2007111733A3 (en) Method for diagnosing, prognosing and treating glioma
MX2009007368A (es) Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
ATE316147T1 (de) Enzymsensor
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
MX2007003094A (es) 4-(metilo ciclico condensado)-imidazol-2-tionas como agonistas alfa2 adrenergicos.
ATE533497T1 (de) Verfahren zur verwendung von hedgehog-kinase- antagonisten zur behandlung von hedgehog- vermittelten krebs
WO2008148115A8 (en) Methods, systems, and kits for evaluating multiple sclerosis
EP1756571B8 (de) Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2006074450A3 (en) Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition